Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Following the rules in marketing

Joel Lexchin
CMAJ September 21, 1999 161 (6) 685-686;
Joel Lexchin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
Loading

[The author responds:]

Murray Elston asks why I did not submit a complaint about the alleged violations that I reported in my letter. In order to engage in the complaints process, one must have some confidence in the system. The process used by the CRBPC does not inspire confidence. Recently a colleague filed a complaint about a company that allegedly had paid accommodation expenses for doctors attending a meeting in southern Ontario. The response of the CRBPC's Marketing Practices Review Committee was that the documentation provided did not support the allegation. Apparently the committee had not even bothered to ask the company if it had paid the hotel expenses.

Suppose that I had filed a complaint and it was upheld. What would the consequences have been? As I have previously documented,1 the CRBPC's reporting procedure on enforcement of its code is markedly nontransparent. No information would be given about who filed the complaint, when the complaint was made, when the violation took place, the product involved, the exact nature of the offense, the reasons why the complaint was upheld or the sanctions imposed. All that would appear in Update, the relatively obscure industry newsletter, is the name of the company and the section of the code that was violated.

Public reporting on all aspects of complaints and violations is critical for a number of reasons. First, it is an important accountability mechanism. Second, it should be considered an integral part of any sanctions against companies. Companies have an incentive to maintain compliance with a code and avoid adverse publicity and a possible deterioration in their public image. Third, public reporting is a good way to inform health care professionals about the existence of a code and its requirements. Above all, it is essential for informing health care professionals about misleading claims to which they have been exposed.2

References

  1. 1.↵
    Lexchin J. Enforcement of codes governing pharmaceutical promotion: What happens when companies breach advertising guidelines? CMAJ 1997;156(3):351-7.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Regulation of prescription drug promotion in Australia. MaLAM Aust News 1996;4(4/5):1-8.
PreviousNext
Back to top

In this issue

CMAJ
Vol. 161, Issue 6
21 Sep 1999
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Following the rules in marketing
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Following the rules in marketing
Joel Lexchin
CMAJ Sep 1999, 161 (6) 685-686;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Following the rules in marketing
Joel Lexchin
CMAJ Sep 1999, 161 (6) 685-686;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • An expanded role for blood donor emerging pathogens surveillance
  • Beyond wastewater surveillance: refining environmental pathogen detection in the built environment
  • Observational evidence in support of screening for depression during pregnancy and the postpartum period
Show more Letters

Similar Articles

Collections

  • Topics
    • Drug regulation
    • Medical ethics

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire